Zacks has a small article on Cytori Therapeutics. This company seeks to commercialize stem and regenerative cell therapies without the need for embryonic stem cells. The company was awarded a patent today for their Celution® System technology.
Since this company is still in the early stages of developing their technology, patience will be in order for stockholders. Zacks is estimating that the company will not be profitable until 2011 and have given the company a $16 price target based on 2012 estimates.